Acorda Therapeutics,Inc. (NASDAQ:ACOR) Files An 8-K Results of Operations and Financial ConditionItem 2.02Results of Operations and Financial Condition
On July 27, 2017, Acorda Therapeutics, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2017. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K, and incorporated by reference into this Item 2.02.
Item 9.01Financial Statements and Exhibits
(d) Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated July 27, 2017 |
ACORDA THERAPEUTICS INC ExhibitEX-99.1 2 acor-ex991_15.htm EX-99.1 acor-ex991_15.htm EXHIBIT 99.1 CONTACT: Felicia Vonella Acorda Therapeutics (914) 326-5146 [email protected] FOR IMMEDIATE RELEASE Acorda Provides Financial and Pipeline Update for Second Quarter 2017 • NDA submitted for INBRIJATM (levodopa inhalation powder) • Tozadenant Phase 3 data expected Q1 2018 • AMPYRA® (dalfampridine) 2Q 2017 net revenue of $131.6 Million; 8% increase over 2Q 2016 • AMPYRA 2017 net sales guidance of $535 – $545 million reiterated • Projected year-end cash balance greater than $200 million ARDSLEY,…To view the full exhibit click here
About Acorda Therapeutics,Inc. (NASDAQ:ACOR)
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza. Its research and development programs include CVT-301, Dalfampridine, Plumiaz, Neuregulin Program, Remyelinating Antibodies Program, CVT-427 and Chondroitinase Program. Its Ampyra is an oral drug for the treatment to improve walking in patients with multiple sclerosis. Zanaflex Capsules and tablets are used as short-acting drugs for the management of spasticity. Qutenza is a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. Its pipeline of neurological therapies addresses a range of disorders, including Parkinson’s disease, chronic post-stroke walking deficits and migraine.
